Pharmacokinetics of rifapentine at 600, 900, and 1,200 mg during once-weekly tuberculosis therapy.
about
Daily dosing of rifapentine cures tuberculosis in three months or less in the murine modelWeekly rifapentine/isoniazid or daily rifampin/pyrazinamide for latent tuberculosis in household contactsTuberculosis, nontuberculous lung infection, pleural disorders, pulmonary function, respiratory muscles, occupational lung disease, pulmonary infections, and social issues in AJRCCM in 2004Advances in the diagnosis and treatment of tuberculosis.Daily rifapentine for treatment of pulmonary tuberculosis. A randomized, dose-ranging trial.Population pharmacokinetics of rifapentine and desacetyl rifapentine in healthy volunteers: nonlinearities in clearance and bioavailabilityEffects of four different meal types on the population pharmacokinetics of single-dose rifapentine in healthy male volunteers.Protein binding of rifapentine and its 25-desacetyl metabolite in patients with pulmonary tuberculosis.Efficient intermittent rifapentine-moxifloxacin-containing short-course regimen for treatment of tuberculosis in mice.Population pharmacokinetics of rifapentine and its primary desacetyl metabolite in South African tuberculosis patients.New approaches in the diagnosis and treatment of latent tuberculosis infectionAn update on the use of rifapentine for tuberculosis therapy.Rifapentine is not more active than rifampin against chronic tuberculosis in guinea pigsNew regimens to prevent tuberculosis in adults with HIV infectionTreatment of latent tuberculosis infection in HIV: shorter or longer?Update in tuberculosis 2005.Dosing schedules of 6-month regimens and relapse for pulmonary tuberculosis.Rifapentine for the treatment of pulmonary tuberculosis.Preliminary pharmacokinetic study of repeated doses of rifampin and rifapentine in guinea pigsPhysiologically Based Pharmacokinetic Model of Rifapentine and 25-Desacetyl Rifapentine Disposition in Humans.Weekly moxifloxacin and rifapentine is more active than the denver regimen in murine tuberculosisNew drugs against tuberculosis: problems, progress, and evaluation of agents in clinical development.Fighting tuberculosis: old drugs, new formulations.Emerging drugs for the treatment of tuberculosis.Optimizing the clinical pharmacology of tuberculosis medications.Rifapentine for the treatment of latent tuberculosis.Rifampin vs. rifapentine: what is the preferred rifamycin for tuberculosis?Effect of administration of moxifloxacin plus rifampin against Mycobacterium tuberculosis for 7 of 7 days versus 5 of 7 days in an in vitro pharmacodynamic system.Costs and cost-effectiveness of four treatment regimens for latent tuberculosis infection.Concentration-dependent Mycobacterium tuberculosis killing and prevention of resistance by rifampin.Rifapentine for the treatment of tuberculosis: is it all it can be?Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis.Pharmacokinetics and pharmacogenetics of anti-tubercular drugs: a tool for treatment optimization?Power of tests for comparing trend curves with application to national immunization survey (NIS).Long-acting formulations for the treatment of latent tuberculous infection: opportunities and challenges.
P2860
Q21144660-EEC65C82-FB83-4544-8EFF-4AD7CC1BFF5BQ24650581-8740A97F-A908-470F-AC8B-26114223740DQ28238675-03E4218E-63DA-4D36-A8A2-9E0D0ED5B3B0Q30353049-E6748A49-8D01-4B0F-AA39-CF070D9D9B1CQ33735589-3CA10DBB-9AE1-4B26-B5E9-909BDDB150E8Q33798061-C05B7C7D-E5CF-4BAA-AE2C-16F13A5189ABQ34045240-75BD22DB-E97F-43AD-BA88-F656931B6D41Q34058356-9372ABCE-F4C1-455C-A4FC-F182D3F84349Q34077125-D3D26B6B-94A0-4F74-BC3A-8B6F94FC61C2Q34123784-504FBF36-867C-4A44-B1CF-677783B0DF34Q34419185-B8FCE098-978C-4492-B288-F3A1EDDC74B6Q35084363-52989C9F-612D-46D8-BC2C-6791626CBE51Q36086369-D49B4E2B-DADF-4618-BB97-5A65489DC16BQ36125227-634A291B-C5CE-4832-BE3A-1FD827E47924Q36137225-ACDB169F-9136-4C10-B6C8-6D250B04006EQ36403165-F4166017-501F-49B3-B563-1230F8E37D85Q36565562-2645D80D-9E17-419D-95E2-02F40E834171Q36643657-97ABAE39-0D68-4329-B184-9B77D70301CDQ36667095-E9EDB556-5902-4D52-B224-F3DB35621BE0Q37120003-FC56A7CB-4D99-46DF-AC6A-B4F28571F206Q37282694-6082BE20-C805-4BA6-8162-9ED8FF172B7FQ37346929-31B641C3-193D-457B-B965-C071F40EADB3Q37579212-35C7CF58-F56A-4B75-AFFE-81E522C2BF89Q37792105-1FC0C3AC-43C6-4324-AD54-2D504031057EQ38542159-26C86629-9F90-470F-849C-C4706F1926A1Q38933165-E382DF6B-85F6-4DDD-A355-8EAFB6CDAABCQ40095703-072A3384-600C-43B3-BAED-AC0A60356381Q41840976-49431A2B-AA72-41E7-A032-C43CE35B4ECEQ42110466-BA5CBA09-7980-41DF-B587-178FF698F82FQ42861000-3EA06518-A799-4E2F-9B80-6B8C9F9C0B32Q44909333-CDF746CD-E088-4B9D-90D1-8303115E4EC9Q46448545-CA8634B5-5825-45B8-8E8B-8558ADAD8269Q47332682-7F15EC5D-12B1-4240-B6AF-CD443AB1C035Q51607269-648C96BA-8C88-4267-B9FF-4718C4CD59BDQ52673482-06EBEB33-C0C3-42B3-92D4-A07BDCE8DB4C
P2860
Pharmacokinetics of rifapentine at 600, 900, and 1,200 mg during once-weekly tuberculosis therapy.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Pharmacokinetics of rifapentin ...... e-weekly tuberculosis therapy.
@en
Pharmacokinetics of rifapentin ...... e-weekly tuberculosis therapy.
@nl
type
label
Pharmacokinetics of rifapentin ...... e-weekly tuberculosis therapy.
@en
Pharmacokinetics of rifapentin ...... e-weekly tuberculosis therapy.
@nl
prefLabel
Pharmacokinetics of rifapentin ...... e-weekly tuberculosis therapy.
@en
Pharmacokinetics of rifapentin ...... e-weekly tuberculosis therapy.
@nl
P2093
P2860
P1476
Pharmacokinetics of rifapentin ...... e-weekly tuberculosis therapy.
@en
P2093
Andrew Vernon
Charles A Peloquin
Katherine Hayden
Marc Weiner
Naomi Bock
Stefan Goldberg
Stephen Weis
Timothy R Sterling
Tuberculosis Trials Consortium
P2860
P304
P356
10.1164/RCCM.200311-1612OC
P407
P577
2004-02-12T00:00:00Z